恒瑞医药(600276.SH)获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant advancement in its drug development pipeline [1] Group 1: Clinical Trials - The company and its subsidiaries, including Shanghai Heng Rui Medicine Co., Ltd. and Suzhou Shengdiya Biopharmaceutical Co., Ltd., have been granted clinical trial approval for SHR-4375 injection, among others [1] - The specific trial for SHR-4375 involves a multicenter, open-label Phase Ib/II study focusing on safety, tolerability, and efficacy in patients with advanced solid tumors [1]